Stratification of patients in NASH clinical trials: A pitfall for trial success.

ABSTRACT: Identifying the most effective therapeutic intervention in patients with NAFLD is challenging. Precise stratification in clinical trials is key to ensuring the inclusion of patients who will benefit (and not those who will be harmed) and/or in whom the natural history can be improved. Clinical trials in NAFLD can provide useful information about the individual components that underlie this complex metabolic disorder and the concomitant medications that could interfere with responses to an experimental intervention. However, to date, clinical trial reporting for NAFLD has been suboptimal, limiting our understanding. Frequently dysmetabolic comorbidities and/or daily habits are not reported or adequately accounted for. Herein, we suggest new strategies to integrate the spectra of comorbiditi

SUBMITTER: Ampuero J 

PROVIDER: S-EPMC7486452 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature